Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc.

0.90
EUR
0.00
(0.00%)
-0.66EPS
12.41MMarket Cap
Apr 01Next Earn

Total Valuation

EUR

As of June 30, 2026, Cocrystal Pharma Inc carries a market capitalization of 12.41M, placing it among publicly traded companies globally. Its enterprise value stands at 11.69M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap12.41M
Enterprise Value11.69M

Important Dates

Cocrystal Pharma Inc's next confirmed earnings release is scheduled for April 1, 2027.

Earnings Date4/1/2027

Share Statistics

As of June 30, 2026, Cocrystal Pharma Inc has 13.79M shares outstanding.

Shares Outstanding13.79M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 40.78, and the price-to-book ratio stands at 13.58.

PS Ratio40.78
PB Ratio13.58
P/TBV Ratio13.58
P/FCF Ratio-1.69
P/OCF Ratio-1.69

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 40.45 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 11.69M versus a market cap of 12.41M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales40.45

Financial Position

As of June 30, 2026, Cocrystal Pharma Inc maintains a current ratio of 1.24, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.

Current Ratio1.24
Quick Ratio1.11
Debt / Equity128.45
Debt / EBITDA-0.14

Financial Efficiency

EUR

Over the twelve months ended June 30, 2026, Cocrystal Pharma Inc posted a negative return on equity (ROE) of -311.68, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -151.10, reflecting losses generated across the asset base. The company generates approximately 28,180.39 in revenue per employee across its workforce of 10.25, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-311.68
Return on Assets (ROA)-151.10
Revenue Per Employee28,180.39
Employee Count10.25

Stock Price Statistics

EUR

As of the close on November 17, 2026, Cocrystal Pharma Inc's stock has gained approximately 1.69% over the past 52 weeks. The 50-day moving average sits at 0.96, while the 200-day moving average is 0.96.

52-Week Price Change1.69%
50-Day Moving Average0.96
200-Day Moving Average0.96

Income Statement

EUR

Over the twelve months ended June 30, 2026, Cocrystal Pharma Inc generated 288,849.00 in revenue and converted that into -8.70M in net income, yielding earnings per share of -0.66. EBITDA reached -8.54M, while operating income came in at -8.85M.

Revenue288,849.00
Operating Income-8.85M
Pretax Income-8.70M
Net Income-8.70M
EBITDA-8.54M
EBIT-8.85M
Earnings Per Share (EPS)-0.66

Balance Sheet

EUR

As of June 30, 2026, Cocrystal Pharma Inc holds 1.90M in cash and equivalents against 1.17M in total debt, resulting in a net debt position of -1.90M. Total book value stands at 913,813.20, with working capital of 542,686.00 providing operational flexibility.

Cash & Cash Equivalents1.90M
Total Debt1.17M
Net Debt-1.90M
Equity (Book Value)913,813.20
Book Value Per Share0.07
Working Capital542,686.00

Cash Flow

EUR

Cocrystal Pharma Inc produced -6.96M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -10,503.60 in capital expenditures, free cash flow totaled -6.97M - equivalent to -0.53 per share.

Operating Cash Flow-6.96M
Capital Expenditures-10,503.60
Free Cash Flow-6.97M
FCF Per Share-0.53

Margins

These figures cover the twelve months ended June 30, 2026. The operating margin of -3,063.64 and net profit margin of -3,011.52 provide insight into operational efficiency.

Operating Margin-3,063.64
Pretax Margin-3,011.52
Profit Margin-3,011.52
EBITDA Margin-2,956.36

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -59.20: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

FCF Yield-59.20

Stock Splits

Cocrystal Pharma Inc's most recent stock split took place on October 11, 2022 with a 12:1 split ratio.

Last Split Date10/11/2022
Split Ratio12:1

Scores

As of June 30, 2026, Cocrystal Pharma Inc has an Altman Z-Score of -109.30, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-109.30